STRO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STRO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sutro Biopharma's annualized ROCE % for the quarter that ended in Dec. 2023 was 60.51%.
The historical data trend for Sutro Biopharma's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
ROCE % | Get a 7-Day Free Trial | -33.14 | -11.50 | -30.84 | -35.42 | -18.08 |
Sutro Biopharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
ROCE % | Get a 7-Day Free Trial | -41.34 | -58.43 | -40.23 | -41.03 | 60.51 |
Sutro Biopharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -64.851 | / | ( ( (406.944 - 66.547) | + | (470.736 - 93.746) ) | / 2 ) | |
= | -64.851 | / | ( (340.397 | + | 376.99) | / 2 ) | |
= | -64.851 | / | 358.6935 | ||||
= | -18.08 % |
Sutro Biopharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | 222.416 | / | ( ( (431.734 - 73.606) | + | (470.736 - 93.746) ) | / 2 ) | |
= | 222.416 | / | ( ( 358.128 | + | 376.99 ) | / 2 ) | |
= | 222.416 | / | 367.559 | ||||
= | 60.51 % |
(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (NAS:STRO) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Sutro Biopharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Hans-peter Gerber | officer: Chief Scientific Officer | C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Brunilda Shtylla | officer: Chief Business Officer | C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Venkatesh Srinivasan | officer: Chief Tech Op Officer | C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anne Elizabeth Borgman | officer: Chief Medical Officer | 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705 |
William J Newell | director, officer: CEO & President | 887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5 |
Heidi Hunter | director | C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
Nicki Vasquez | officer: Chief Port. Strat & Alnce Ofcr | C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
Jane Chung | officer: Chief Commercial Officer | C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
Trevor Hallam | officer: Chief Science Officer | PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Jon Marc Wigginton | director | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
John Gordon Freund | director, 10 percent owner | 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301 |
Arturo Md Molina | officer: Chief Medical Officer | 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024 |
Linda A Fitzpatrick | officer: Chief People & Comm. Officer | NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085 |
James P Panek | director | C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005 |
Matsui Connie | director | 3030 CALLAN RD, SAN DIEGO CA 92121 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 12-10-2022
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 04-27-2023
By Tiesvg Tiesvg • 12-21-2022
By sperokesalga sperokesalga • 03-01-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 03-30-2023
By Tiesvg Tiesvg • 12-20-2022
By Marketwired • 08-10-2023
By Value_Insider Value_Insider • 11-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.